Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > REGULATORY
REGULATORY
- PMDA Reveals Zero Company Request So Far for MID-NET Database Use, but Says Several Interested
June 19, 2018
- Japan Cabinet Adopts 2018 Honebuto Policy, Inscribes Possible HTA Use in New Drug Listing
June 18, 2018
- Authorized Generics for Aimix, Cravit IV Join NHI Price List
June 15, 2018
- Chuikyo Agrees on No Willing-to-Pay Cost Survey before CEA Rollout; Experts Say Pilot ICER Thresholds “Justifiable”
June 14, 2018
- Keytruda/Ibrance Added to Pilot CEA Drug List, but There Won’t Be Price Tweaks
June 14, 2018
- Japan’s 1st Conditional OK Might Come This Autumn for Pfizer’s Next-Gen ALK Inhibitor Lorlatinib
June 13, 2018
- LDP’s Eto Study Group Submits Proposal to Health Minister
June 13, 2018
- PMDA to Promote Development of Next-Generation Drugs by Improving Its Science Level in Drug Evaluation
June 13, 2018
- MHLW to Study Ways to Increase Transparency of Process for Including Vaccines in Public Vaccination Programs
June 12, 2018
- MHLW’s New Anti-RA Measures Likely to Push Proper Use of Pricy Biologics
June 11, 2018
- MHLW Panel Gives Thumbs-Up for Entyvio, Official Nod Expected This Month
June 11, 2018
- Further Price Cuts for Off-Patent Drugs Erased from Draft Honebuto Paper
June 11, 2018
- Panel Members Positive about Going Digital on Package Inserts: HSC
June 11, 2018
- Govt Should Screen Drug Promotion Material, Scope of Information Provided: HSC Member
June 8, 2018
- Experts Support Plan to Seize Improperly Earned Revenue as in Diovan Case: HSC
June 8, 2018
- AMED Discloses Individual R&D Project Funding; 31 Receive Funding of Over 1 Billion Yen
June 7, 2018
- Deregulation Panel Pushes PMDA to Digitalize Process
June 6, 2018
- Reward Innovation to Solve Social Challenges: LDP Study Group
June 6, 2018
- Japan Eyes Economic Assessments for New Drug Listing: Draft Honebuto Paper
June 6, 2018
- Large Vessel Vasculitis to Be Added to Significant Adverse Reactions for G-CSF Preparations: MHLW
June 6, 2018
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…